The Role of Mass Spectrometry in Hepatocellular Carcinoma Biomarker Discovery

Hepatocellular carcinoma (HCC) is the main liver malignancy and has a high mortality rate. The discovery of novel biomarkers for early diagnosis, prognosis, and stratification purposes has the potential to alleviate its disease burden. Mass spectrometry (MS) is one of the principal technologies used...

Full description

Saved in:
Bibliographic Details
Published inMetabolites Vol. 13; no. 10; p. 1059
Main Authors Shen, Eric Yi-Liang, U, Mei Ran Abellona, Cox, I. Jane, Taylor-Robinson, Simon D
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.10.2023
MDPI
Subjects
Biological markers
Biomarkers
Health aspects
Hepatocellular carcinoma
Hepatoma
Lipids
Liver cancer
Malignancy
Mass spectrometry
Mass spectroscopy
Medical research
Medicine, Experimental
Metabolites
Metabolomics
Nuclear magnetic resonance
Physiological aspects
Review
Taiwan
Asia
Africa
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is the main liver malignancy and has a high mortality rate. The discovery of novel biomarkers for early diagnosis, prognosis, and stratification purposes has the potential to alleviate its disease burden. Mass spectrometry (MS) is one of the principal technologies used in metabolomics, with different experimental methods and machine types for different phases of the biomarker discovery process. Here, we review why MS applications are useful for liver cancer, explain the MS technique, and briefly summarise recent findings from metabolomic MS studies on HCC. We also discuss the current challenges and the direction for future research.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2218-1989
2218-1989
DOI:10.3390/metabo13101059